Company news

Annexon, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Annexon Biosciences Appoints Bettina M. Cockroft, M.D. to its Board of Directors

January 19, 2022

Annexon Biosciences Reports Promising Interim Phase 2 Data Showing Improvement in Clinical Measures with ANX005 in Huntington’s Disease Following Six-Month Treatment

January 3, 2022

Annexon Biosciences Announces Clinical and Preclinical Data Highlighting Potential of Complement-Targeting Programs at the 63rd ASH Annual Meeting & Exposition

December 12, 2021

Annexon Biosciences Announces Business and Program Highlights and Reports Third Quarter 2021 Financial Results

November 8, 2021

Annexon Biosciences Further Strengthens Its Executive Leadership Team With Appointment of Ted Yednock, Ph.D., to Chief Innovation Officer and Appointment of Larry Mattheakis, Ph.D., as Chief Scientific Officer

October 3, 2021

Annexon Biosciences Reports Second Quarter 2021 Financial Results and Provides Mid-Year Business Update

August 15, 2021

Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases

July 21, 2021

Annexon Biosciences Provides Business Update and Reports First Quarter 2021 Financial Results

May 16, 2021

Annexon Biosciences Reports Fourth Quarter and Full-Year 2020 Financial Results with Recent Business Highlights

March 24, 2021

Annexon Advances Classical Complement Platform with Initiation of Global Phase 2 ARCHER Trial in Patients with Geographic Atrophy

February 28, 2021

Annexon Welcomes William H. Carson, M.D. to the Board of Directors

February 7, 2021

Annexon Announces Initiation of Phase 2/3 Trial of ANX005 in Patients with Guillain-Barré Syndrome

December 20, 2020

Annexon Biosciences Reports Third Quarter 2020 Financial Results and Recent Business Highlights

November 15, 2020

Annexon Expands Classical Complement Platform into Neurodegenerative Diseases of the Brain with Initiation of Huntington’s Disease Clinical Program

November 11, 2020

Annexon Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights

September 7, 2020

Annexon Biosciences Expands Leadership Team with the Appointment of Michael Overdorf as Chief Business Officer

July 29, 2020

Annexon Announces Closing of Initial Public Offering

July 27, 2020

← Newer news releases

Calls

Decks

The 5 newest of 23 decks. Every deck is listed under its year.